# Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases

**Authors:** Nutchaya Sukon, Pitipol Choopong, Usanee Tungsattayathitthan, Nattaporn Tesavibul, Wilawan Sanpan, Sutasinee Boonsopon

PMC · DOI: 10.1007/s10792-024-02980-7 · 2024-02-08

## TL;DR

This study explores the link between skin autofluorescence and uveitis/scleritis activity in patients with immune-related eye inflammation.

## Contribution

The study investigates advanced glycation end products as potential biomarkers for uveitis/scleritis activity.

## Key findings

- No significant difference in SAF AGE levels between patients and controls.
- Lower SAF AGE levels were significantly associated with active ocular inflammation.
- SAF AGE levels were not found to be a reliable biomarker for uveitis/scleritis activity.

## Abstract

To investigate for association between skin autofluorescence (SAF) advanced glycation end products (AGEs) and uveitis/scleritis activity in systemic inflammatory disease-related active non-infectious uveitis/scleritis patients.

This cross-sectional study was conducted at Siriraj Hospital during October 2019 to March 2020. AGEs were measured by SAF method in systemic immune-related disease patients with active uveitis/scleritis, and those results were compared with those of healthy age-matched controls.

Thirty-one active non-infectious uveitis/scleritis patients and 31 age-matched controls were enrolled. The mean age of patients was 40.0 ± 12.8 years, and most were female (55.0%). The most common associated systemic immune-related disease was Vogt–Koyanagi–Harada disease (n = 14). Mean SAF AGE level in the study group compared to the control group was 2.38 ± 0.66 arbitrary units (AU) versus 2.58 ± 0.56 AU, respectively (p = 0.20). Multivariate analysis showed decreased SAF AGE level to be significantly associated with active ocular inflammation, (odds ratio: 0.01, 95% confidence interval: 0.00004–0.81; p = 0.04).

SAF AGE level was not so far found to be a reliable biomarker for indicating uveitis/scleritis activity in systemic immune-related disease patients with active ocular inflammation.

Thai Clinical Trials Registry, https://www.thaiclinicaltrials.org/. (Reg. No. TCTR20200114004, registered date 01/01/2020, beginning date of the trial 10/01/2019).

## Linked entities

- **Diseases:** uveitis (MONDO:0020283), scleritis (MONDO:0001718), Vogt–Koyanagi–Harada disease (MONDO:0018092)

## Full-text entities

- **Genes:** RENBP (renin binding protein) [NCBI Gene 5973] {aka RBP, RNBP}
- **Diseases:** ocular inflammation (MESH:D007249), uveitis (MESH:D014605), immune-mediated ocular inflammatory diseases (MESH:C567355), systemic inflammatory disease (MESH:D018746), systemic immune-related disease (MESH:D007154), scleritis (MESH:D015423), Vogt-Koyanagi-Harada disease (MESH:D014607)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10853306/full.md

---
Source: https://tomesphere.com/paper/PMC10853306